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Lassa virus is an Old World arenavirus endemic to West Africa that
causes severe hemorrhagic fever. Vaccine development has fo-
cused on the envelope glycoprotein complex (GPC) that extends
from the virion envelope. The often inadequate antibody immune
response elicited by both vaccine and natural infection has been,
in part, attributed to the abundance of N-linked glycosylation on
the GPC. Here, using a virus-like−particle system that presents
Lassa virus GPC in a native-like context, we determine the com-
posite population of each of the N-linked glycosylation sites pre-
sented on the trimeric GPC spike. Our analysis reveals the presence
of underprocessed oligomannose-type glycans, which form punc-
tuated clusters that obscure the proteinous surface of both the
GP1 attachment and GP2 fusion glycoprotein subunits of the Lassa
virus GPC. These oligomannose clusters are seemingly derived as a
result of sterically reduced accessibility to glycan processing en-
zymes, and limited amino acid diversification around these sites
supports their role protecting against the humoral immune re-
sponse. Combined, our data provide a structure-based blueprint
for understanding how glycans render the glycoprotein spikes of
Lassa virus and other Old World arenaviruses immunologically
resistant targets.
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Lassa virus (LASV), an arenavirus endemic to rodent pop-ulations in West Africa, causes severe hemorrhagic fever
upon transmission to humans, with an estimated 300,000 infec-
tions and several thousand deaths each year (1). To date, no li-
censed vaccine exists against LASV and there are no approved
therapeutics for treatment, although the compassionate use of the
antiviral drug ribavirin alone, or in combination with favipiravir,
has shown efficacy if administered early in infection (2). The in-
consistent induction of potent LASV-specific antibody immunity,
both during natural infection and by vaccination attempts (3–7), is
thought to be partly due to the extensive glycosylation presented
on the surface of the LASV glycoprotein complex (GPC) (8).
While the architecture of the protein components of LASV GPC
is well understood (9–12), structural knowledge of the immuno-
logically important glycans displayed on the GPC surface has
remained elusive.
The arenaviral GPC is encoded by the S segment of the single-
stranded, bisegmented RNA genome. Following expression of a
single polyprotein precursor, the GPC is proteolytically pro-
cessed by the host cell subtilase SKI-1/S1P (13) and displayed on
the lipid bilayer surface of the mature virion as a trimer of het-
erotrimers (11, 14). Each heterotrimer consists of a receptor-
binding GP1 domain (10, 15–19), a GP2 class I membrane fu-
sion protein (10, 19–21), and a retained myristoylated stable
signal peptide (SSP), which is required for GPC processing and
function (22–24). Host cell entry of Old World arenaviruses and
Clade C New World arenaviruses is initiated by GPC-mediated at-
tachment to O-mannose glycans containing xylose-glucuronic acid
sugar repeats presented on the cell surface receptor, α-dystroglycan
(α-DG) (25–28). Factors including the lowered pH associated with
entry into the endocytic pathway, lysosome-associated membrane
protein 1 (LAMP1) recognition, and dissociation of GP1 from the
GPC are responsible for triggering fusion of the viral envelope and
endosomal host cell membrane (11, 29, 30).
The 11 potential N-linked glycosylation sites (PNGs) found on
each SSP−GP1−GP2 protomer accounts for nearly 30% of the
total mass of the LASV GPC (10, 31). It has been shown that
LASV glycans promote evasion from the neutralizing antibody
response and are required for viral fitness (8). Additionally, under-
processed oligomannose-type glycans on LASV GPC augment
infection through interaction with the C-type lectin, dendritic cell-
specific ICAM-3−grabbing nonintegrin (DC-SIGN) (32). However,
the relative abundance and distribution of these underprocessed
glycans and fine structure of the LASV glycome have yet to be
determined.
Here, using an established virus-like–particle (VLP) system
(11, 14), we provide a global and site-specific analysis of the N-
linked glycosylation presented on LASV GPC. Our analysis reveals
extensive global heterogeneity, ranging from highly processed
complex-type glycosylation to underprocessed oligomannose-type
glycans. Mapping of these glycans onto the structure of the LASV
GPC ectodomain reveals that some of these carbohydrates form a
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dense shield consisting of clusters of oligomannose-type glycans
that are likely to be utilized during DC-SIGN−mediated entry.
Sequence analysis of LASV isolates reveals a higher incidence of
amino acid variation on the surface of the GPC in regions less
occluded by N-linked glycosylation. Together, these data reveal
how host cell-derived glycosylation renders LASV an immuno-
logically challenging target.
Results
Glycan Processing of Trimeric LASV GPC. LASV encodes a large
number of N-linked glycosylation sequons on both the GP1 and
GP2 subcomponents of the GPC (Fig. 1A). We sought to char-
acterize the composition of the carbohydrate structures displayed
on the mature LASV GPC spike using a previously established
VLP production and purification strategy, which displays LASV
GPC in the full native assembly (11, 14, 33). Western blot analysis
of secreted VLPs using an anti-LASV GP1 (14) monoclonal an-
tibody and anti-LASV GP2 polyclonal antibody (34) confirmed
the presence and maturation of the GPC into GP1 and GP2
subunits (Fig. 1B). Electron cyromicroscopy further verified the
expected display of globular GPC spikes on the surface of the
purified VLPs (Fig. 1C).
To quantitatively assess the composition of the LASV GPC
glycosylation, enzymatically released N-linked glycans were flu-
orescently labeled, and subjected to hydrophilic interaction
chromatography−ultra-performance liquid chromatography
(HILIC-UPLC) analysis. Cleavage of the released glycan pool with
endoglycosidase H (Endo H) revealed an abundance (49%) of
oligomannose-type glycans (Fig. 2A), particularly Man6–9GlcNAc2
glycoforms. We observed only a minor population of Man5GlcNAc2,
suggesting the limited processing by Golgi-resident α-mannosidases
to convert Man6GlcNAc2 to Man5GlcNAc2 at specific sites. The
high proportion of oligomannose-type glycans on the LASV GPC is
consistent with previous lectin-binding and glycosidase digestion
studies (35, 36), which revealed underprocessed glycans on
recombinant LASV GP1 constructs, albeit to varying levels.
We ascertained the precise structure of each of the glycans
within the released pools by negative-ion mobility−electrospray ion-
ization mass spectrometry (IM-ESI MS) (Fig. 2B). Consistent with
the UPLC data, IM-ESI MS confirmed a dominant oligomannose-
type glycan population, lacking the level of sialylation characteristic
to most host cell surface glycoproteins (37, 38).
To confirm the composition of these oligomannose-type gly-
cans, fragmentation by collision-induced dissociation was per-
formed. This analysis reveals the expected array of underprocessed
Man5–9GlcNAc2 species that form following processing by endo-
plasmic reticulum (ER)-resident α-glucosidases I and II (SI Ap-
pendix, Fig. S1) (39). Consistent with the biological preference of
ER α-mannosidase I to remove the three-branched mannose of the
six-antenna (D2) from Man9GlcNAc2 during N-linked glycan
processing (40), MS/MS of Man8GlcNAc2 exhibits a single set of
ions derived from a particular (D1, D3) isomer (SI Appendix, Fig.
S1B). We observed two Man7GlcNAc2 isomers, with the seventh
mannose located on either the six-antenna (D3) or three-antenna
(D1) arm (SI Appendix, Fig. S1C). These isomers have also been
observed in HIV-1 (gp120) and Semliki Forest virus E1 and E2
glycoproteins (41, 42); it is likely that the existence of high levels of
oligomannose glycans among such pathobiologically diverse viruses
arises from a requirement for conserved immune evasion and re-
ceptor recognition functionality, respectively.
Structural Clustering of Underprocessed Glycans on the GPC. It has
been previously shown that oligomannose-type glycans displayed
on the LASV GPC mediate host cell attachment to DC-SIGN
presented on monocyte-derived dendritic cells (32). We sought
to identify the possible location(s) of this interaction using an
integrated site-specific compositional and structural approach.
LASV GPC glycopeptides were generated by digestion with
trypsin, chymotrypsin, and GluC and subjected to in-line liquid
chromatography−mass spectrometry. This analysis revealed that
each site presents a differential level of oligomannose, hybrid,
and complex-type glycan populations (Fig. 3A). Consistent with
our UPLC analysis (Fig. 2A), we observed that a number of these
sites (Asn79GP1, Asn89GP1, Asn99GP1, Asn365GP2, and Asn373GP2)
were predominantly of the oligomannose type. The level of man-
nosylation varies widely across these sites, where the glycans at
Asn79GP1 and Asn365GP2 present a dominant population of Man9-
GlcNAc2 and Asn89GP1, Asn99GP1, and Asn373GP2 exhibit less re-
strictive processing and display Man6GlcNAc2 and Man7GlcNAc2.
Using the crystal structure of the trimeric LASV GP1−GP2
ectodomain [Protein Data Bank (PDB) ID code 5VK2 (10)], we
determined the distribution of the observed glycan populations
in a structural context. We generated a model of the fully gly-
cosylated LASV GP1−GP2 ectodomain by overlaying our ex-
perimentally determined glycan structures onto crystallographically
Fig. 1. Preliminary characterization of LASV VLPs. (A) Schematic represen-
tation of LASV GPC, showing the position of N-linked glycosylation amino
acid sequons (NXT/SX, where X ≠ P), SSP, GP1 attachment glycoprotein, GP2
fusion glycoprotein, and transmembrane domain (TMD). (B) Western blot
analysis of purified LASV VLPs performed using anti-GP1 (14) and anti-GP2
(34) antibodies, against native and deglycosylated LASV GPC. Blots show
LASV GP1 and GP2 before and after PNGase F treatment. (C) Electron cry-
omicroscopy image of VLPs purified from MDCK-II cells. White arrows in-
dicate the positions of prominent LASV GPC spikes. (Scale bar, 50 nm.)
Fig. 2. Compositional analysis of LASV GPC glycosylation. (A) HILIC-UPLC
profile of fluorescently labeled N-linked glycans from LASV GPC produced
in VLPs. Oligomannose-type glycans (M5 to M9; Man5GlcNAc2-Man9GlcNAc2)
(green) and complex-type glycans (pink) were identified by Endo H di-
gestion, with quantification of major glycan types summarized as a pie chart.
(B) Negative-ion electrospray spectrum of N-linked glycans from the GPC.
Peaks are annotated with the corresponding compositions, using Consor-
tium for Functional Glycomics symbolic nomenclature and Oxford system
linkages (65), as per the key. Oligomannose-type glycan m/z values are la-
beled in green.
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observed N-linked glycosylation sites (Fig. 3B). This analysis re-
veals how N-linked glycosylation envelopes the majority of the
GPC ectodomain and provides a structure-based model for un-
derstanding glycan-mediated shielding of the proteinous LASV
GPC surface. At a more detailed level, this integrated structural
approach also indicates the existence of a high mannose cluster,
which spans GP1 and GP2 subunits. This cluster is located on the
side of the GPC trimer and includes Asn79GP1, Asn89GP1,
Asn99GP1, Asn365GP2, and Asn373GP2. We suggest that the dom-
inant oligomannose (94%) composition observed in this region is
likely due to the high spatial density of N-linked glycans, which
limit the accessibility of glycan processing enzymes to these sites.
The existence of such a high mannose cluster has precedence and
is reminiscent of the “mannose patches” observed on the glycan
shield of the HIV-1 envelope glycoprotein (43–45). Further ex-
amination reveals that the proposed LAMP1 binding site is par-
tially occluded by this oligomannose cluster. In particular, the
glycan extending from Asn89 shields the histidine triad (His92,
His93, and His230) of LASV GP1 thought to be a region critical
for this interaction (28, 29). The occlusion of this binding site is
consistent with the proposed mechanism of LASV GPC−LAMP1
recognition (11, 15, 30), which requires pH-dependent conforma-
tional rearrangements of the GPC spike upon exposure to the
late endosomes. Indeed, modeling indicates that the formation
of the low-pH LASV GP1 conformation redirects the glycan
extending from N89 to create a LAMP1-accessible recognition
site (SI Appendix, Fig. S2).
Restricted glycan processing also occurs at Asn119, albeit to a
lesser extent (33% oligomannose composition), at the membrane-
distal apex of the trimer (Fig. 3B). Interestingly, Asn119 is located
near, but does not occlude, residues proposed to be required for
α-DG binding (His141, Asn146, Phe147, and Tyr150) (27), and a
lymphocytic choriomeningitis virus GPC N119Q site-directed muta-
tion revealed that the Asn119 glycan protects the α-DG receptor
binding site from antibody-mediated neutralization (8). The use of N-
linked glycosylation to obstruct immunodominant receptor-binding
sites has been observed for other highly glycosylated viruses, such
as the CD4 binding site on the envelope spike of HIV-1 (46) and the
sialic acid binding site on the HA of influenza virus (47).
Amino Acid Sequence Diversification Occurs at Antibody-Accessible
Sites on the GPC. The absence of an effective antibody response
is a characteristic feature of patients who succumb to LASV
infection (3–7). Indeed, extensive affinity maturation is thought
to be required to generate tightly binding antibodies capable of
targeting and neutralizing the highly glycosylated GPC (48).
We sought to quantify the steric role that GPC-displayed glycans
play in shielding the GPC surface. Using publicly available
LASV GPC gene sequences, we performed a comparative non-
synonymous to synonymous nucleotide substitutions (i.e., dN/dS
ratio) analysis of the two major lineages, predominantly found in
Nigeria and Sierra Leone (Fig. 4A and SI Appendix, Fig. S3).
Consistent with a recent dN/dS analysis on LASV GPC (49),
the mean dN/dS ratios for the Nigeria and Sierra Leone clades
were estimated at 0.060 and 0.063, respectively. Using the crystal
structure of LASV GPC, we found that solvent-accessible resi-
dues were characterized by significantly higher dN/dS (mean dN/dS
ratios estimated at 0.070 and 0.080 for the Nigeria and Sierra
Leone lineages, respectively), compared with buried residues
(mean dN/dS ratios estimated at 0.015 and 0.028 for the Nigeria
Fig. 3. Compositional analysis and structure-based
mapping of LASV GPC N-linked glycans. (A) Quanti-
tative site-specific N-linked glycan analysis of LASV
GPC. Purified LASV GPC was digested with trypsin,
chymotrypsin, and GluC, then analyzed by LC-ESI MS.
Glycan compositions are based on the glycan library
generated from negative-ion mass spectrometry of
released N-glycans. The bar graphs represent the
relative quantities of each glycan group with
oligomannose-type glycan series (M9 to M5; Man9-
GlcNAc2 to Man5GlcNAc2) (green), afucosylated and
fucosylated hybrid glycans (Hybrid & F Hybrid)
(dashed pink), and complex glycans grouped
according to fucosylation and number of antennae
(A1 to FA4) (pink). The pie charts summarize the
quantification of these glycans. (B) Modeling ex-
perimentally observed glycosylation onto the crystal
structure of the trimeric LASV GPC (PDB ID code
5VK2) (9). The glycans are colored according to the
oligomannose content, as defined by the upper-
right-hand key. The locations of α-DG and LAMP1
binding sites have been previously proposed (11, 15,
27, 66) and are annotated in cyan and dark blue,
respectively. GP1 and GP2 are colored light gray and
dark gray, respectively.
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and Sierra Leone lineages, respectively) (Fig. 4B). Interestingly,
when mapped onto the structure, amino acids corresponding to
nucleotides with the greatest relative number of nonsynonymous
substitutions colocalized to regions of the GPC surface with
lower levels of glycan density (Fig. 4C), distal from the func-
tionally required α-DG binding site (50). These data provide a
structural rationale for how protein surfaces occluded by glycan
density are shielded from the humoral antibody response of the
host and also rationalize previous suggestions that immune se-
lection is a predominant driver of nonsynonymous substitutions
for accessible regions of the LASV GPC (49).
On a broader level, we note the stringent conservation of
LASV GPC N-linked glycosylation sequons across Old World
arenaviruses, including the five glycan sites that constitute the
LASV mannose cluster (Fig. 5A), suggesting that mannose
patches may be inherent features of Old World arenaviral GPCs.
In contrast, the glycan sites constituting the GP1 component of
the mannose patch are less prevalent in New World arenaviral
GPCs. This juxtaposition may be due to contrasting functional
restraints (for example, the requirement to use transferrin re-
ceptor rather than α-DG). We suggest that such differential
levels of N-linked glycosylation site conservation on the GP1 may at
least partially account for the contrasting locations of immunodo-
minant neutralizing epitopes on New World (the GP1 subunit) and
Old World (GP1−GP2 interfaces) GPCs (10, 18, 51, 52).
Discussion
While the LASV GPC constitutes a key therapeutic target,
vaccine design efforts have been hindered by the host-derived
glycosylation that encompasses the protein surface (8). Here,
using an established VLP expression strategy, we performed a
comprehensive compositional investigation of the LASV gly-
come. Our LASV GPC was produced in MDCK-II cells and
forms a native-like conformation on the surface of the VLP (Fig.
1 B and C) (11, 14, 33). Although MDCK-II cells do not rep-
resent a natural host cell type, due to the stringent conservation
of the N-linked glycan biosynthesis processing pathway (39)
across mammalian cell types (53, 54), we expect only limited
variations in the composition and abundance of the N-linked
glycosylation of LASV GPC. Additionally, we note that the
HIV-1 glycome is determined by structural constraints and is
compositionally well conserved when produced in varied mam-
malian cell types (55). We suggest that future studies on the
glycosylation state of circulating viruses in LASV-infected pa-
tients should corroborate our findings.
We present a structure-based model for rationalizing glycan-
mediated shielding of LASV GPC from the humoral host re-
sponse, revealing a cluster of underprocessed glycans that spans
both the GP1 and GP2 subunits of the trimeric spike complex
(Fig. 3). While the presence of mannose-rich glycosylation is
unusual for cellular proteins, it has often been observed on
enveloped viruses, such as orthomyxoviruses, phleboviruses,
alphaviruses, and flaviviruses (56). The principles rationalizing
the extent of glycan processing of viral proteins have yet to be
fully elucidated and should be considered in the context of the route
of egress from the host cell. In the case of LASV, however, we
suggest that the formation of underprocessed moieties is likelyFig. 4. Amino acid sequence diversification across the LASV GPC. (A) Site-
wise dN/dS analysis of LASV GPC gene sequences from the Nigeria (red,
lineage II) and Sierra Leone (blue, lineage IV) lineages. (B) Comparison of dN/
dS values between buried (b) and solvent-accessible (sa) residues on the
LASV GPC for Nigeria (NGA) and Sierra Leone (SLE). The error bars corre-
spond to the 95% highest posterior density intervals, while circles indicate
mean dN/dS values. (C) Mapping of per residue dN/dS values presented in A
onto the crystal structure of LASV GPC (PDB ID code 5VK2) (9). LASV GPC is
presented as a cartoon with residues colored according to dN/dS values.
Residues with elevated dN/dS values are colored in red, and N-linked gly-
cans are presented as white surfaces. The putative α-DG binding site is
shown in dark blue (27). The interprotomer epitope of Fab 37.7H on LASV
GPC is also shown.
Fig. 5. N-linked glycosylation site conservation across Old and New World
arenaviruses. (A) Glycan site conservation across arenaviruses following se-
quence alignment with Jalview (67). GenBank accession codes for the are-
navirus glycoprotein sequences used in this analysis are listed in SI Appendix,
Fig. S4. Glycan sites are numbered according to the nomenclature estab-
lished by Sommerstein et al. (8), with those present on LASV GPC labeled
with asterisks. (B and C) The positions of (B) Old World and (C) New World
arenavirus N-linked glycosylation sequons mapped onto the structure of
LASV GPC (PDB ID code 5VK2) (9). Spheres are colored according to the level
of conservation of each glycosylation site.
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enabled by the local structural environment and that the proximity
of glycans extending from Asn79GP1, Asn89GP1, Asn99GP1,
Asn365GP2, and Asn373GP2 sterically impede accessibility to glycan-
processing enzymes (SI Appendix, Fig. S5). Oligomannose-type
glycans were also observed at sites outside of this cluster, albeit at
lower levels. The presence of oligomannose at multiple locations
across the GPC is suggestive of a promiscuous model of DC-SIGN
usage, where numerous N-linked glycans may contribute as at-
tachment factors for LASV entry.
The existence of a large population of oligomannose-type
structures on LASV GPC has important consequences in the
development and production of recombinant vaccine candidates.
On recombinant glycoproteins, oligomannose-type glycans are
considered to impart elevated clearance rates and may influence
immunogenicity (57, 58). In addition, from immunogen design
efforts for HIV, we have learned that the levels of oligomannose-
type glycans on recombinant mimics of the envelope spike are
highly sensitive to the structural constraints imposed by native-
like trimeric oligomeric architecture (44, 55). Given the impor-
tance of both glycan processing states and native quaternary
architecture, it is likely that the current recombinant expression
technologies for LASV GP1 (15, 35, 36) and GPC (10) mono-
meric ectodomains may not reproduce native-like glycosylation.
We envisage that the next generation of full-length LASV GPC
ectodomain immunogens will both exhibit trimeric architecture
and suppress the exposure of natively inaccessible epitopes
through the presentation of more-native-like glycosylation.
This study also reveals that amino acid diversification occurs
primarily at glycan-devoid regions on the LASV GPC (Fig. 4),
providing important clues to what sites may be most vulnerable
to the antibody immune response. By analogy to template-based
vaccinology approaches against “evasion-strong” pathogens (59),
such as HIV-1, it is possible that these regions are viable targets
for the development of immunogens capable of effectively
neutralizing LASV.
Continued emergence and high pathogenicity render LASV
an important human pathogen and underscore the necessity for
reagents capable of preventing and treating infection. Given the
prominence of N-linked glycosylation on the LASV surface, we
suggest that the compositional and structural data presented
here will be integral for the creation of a humoral immunity-
based vaccine capable of mimicking the mature LASV virion.
Materials and Methods
Expression and Purification of LASV VLPs. MDCK-II cells stably expressing LASV
GPC (Josiah strain, GenBank ID code AY628203) were cultured in DMEM
supplemented with 10% FCS for 96 h. The medium was replaced with DMEM
with 2% FCS for VLP expression, as previously described (14). After 96 h, the
cell supernatant was cleared by centrifugation (4,000 × g for 30 min). VLPs
were pelleted through 10 mL of 20% sucrose cushion by ultracentrifugation
(170,000 × g for 3 h). The pellets were resuspended in SPG buffer at pH 8 for
12 h at 4 °C.
Western Blot Analysis. Proteins from LASV VLPs were analyzed by Western
blotting, as previously described (11). Monoclonal mouse antibody AC1
against GPC and GP1 and polyclonal rabbit antibody GP4 against GPC and
GP2 were used as primary antibodies.
Electron Cyromicroscopy of VLPs. A 3-μL aliquot of purified VLP samples was
applied on a plasma-cleaned grid coated with holey carbon (C-flat; Proto-
chips). The grids were floated on a drop of 200-μL PBS buffer to remove
sucrose and were blotted for 3 s followed by plunge-freezing into a mixture
of liquid ethane (37%) and propane (63%) using a plunger device (CP3;
Gatan). Micrographs were collected at liquid nitrogen temperature using a
300-kV transmission electron microscope (TF30 Polara; FEI) equipped with a
CCD camera (Ultrascan 4000SP; Gatan) at a calibrated magnification of
75,000×, resulting in a final pixel size of 2 Å/pixel.
Release and Labeling of N-Linked Glycans. Excised LASV GPC gel bands were
washed alternately with acetonitrile and water before drying in a vacuum
centrifuge. The bands were rehydrated with 100 μL of water and incubated
with PNGase F at 37 °C overnight. Released N-linked glycans were
fluorescently labeled with procainamide. A 100-μL aliquot of labeling mix-
ture (110 mg/mL of procainamide and 60 mg/mL of sodium cyanoborohy-
drate in 70% DMSO and 30% glacial acetic acid) was added to the sample
and incubated at 65 °C for 4 h. Labeled glycans were purified using Spe-ed
Amide 2 columns (Applied Separations), as previously described (43).
Glycan Analysis by HILIC-UPLC. Labeled glycans were analyzed using a
2.1 mm × 10 mm Acquity BEH Glycan column (Waters) on a Waters Acquity H-
Class UPLC instrument as performed in ref. 43, with wavelengths λex = 310 nm
and λem = 370 nm. Endo H digestions of labeled glycans were used to measure
abundance of oligomannose-type glycans, as previously described (43).
Mass Spectrometry of Glycans. IM-ESI MS and tandemMS of released N-linked
glycans were performed on a Synapt G2Si instrument (Waters) as previously
described (44). Glycans were purified on a Nafion membrane before in-
jection. Data acquisition and processing were carried out using MassLynx
v4.11 and Driftscope version 2.8 software (Waters).
Mass Spectrometry of Glycopeptides. Aliquots of 150 μg to 200 μg of the VLPs
were proteolytically digested using trypsin, chymotrypsin, and GluC (Promega).
ProteoExtract Glycopeptide Enrichment Kit (Merck Millipore) was used to
enrich glycopeptides for LC-ESI MS. For site-specific analysis of LASV GPC
glycosylation, enriched glycopeptides were analyzed on an Orbitrap Fusion
Tribrid mass spectrometer (Thermo Fisher Scientific) coupled to an EASY-Spray
nano-LC system (Thermo Fisher Scientific). MS data were acquired with
XCalibur 4.0 (Thermo Fisher Scientific). Glycopeptides were fragmented using
both higher-energy collisional dissociation and energy transfer dissociation.
Data analysis and glycopeptide identification were performed using Byonic
and Byologic software (Protein Metrics).
Phylogenetic and Molecular Evolution Analysis. Publicly available sequences
encoding the GPC spike were downloaded from GenBank and manually
aligned. The sequence alignment comprised 217 sequences, spanning
1,473 bp of GPC region. A maximum likelihood phylogeny was inferred using
randomized axelerated maximum likelihood (RAxML), where the model
parameters included general time reversible model with rate categories
(GTRCAT) substitutional model and rapid bootstrap analysis with 100 boot-
strap samples (60). The resulting phylogeny indicated two distinct lineages
that were supported by high bootstrap score (i.e., >0.95). Specifically, one
lineage was dominated by sequences from Nigeria, while the other was
predominantly observed in Sierra Leone. Since these two lineages likely
represent independent epidemics, we estimated site-wise dN/dS ratios and
mean amino acid diversity for each lineage. For the dN/dS analysis, Bayesian
molecular clock phylogenies were estimated using Bayesian evolutionary
analysis and sampling trees (BEAST) v1.8.4 (61). We assumed a strict molecular
clock, Bayesian Skyline coalescent prior, and a codon-structured substitution
model (62). Multiple independent Markov chain Monte Carlo (MCMC) runs of
10 million steps were executed to ensure stationarity and convergence had
been achieved. An empirical distribution of 4,500 molecular clock phylogenies
was obtained by combining (after the removal of burn-in) the posterior tree
distributions from the separate runs, used to estimate dN/dS ratios using re-
naissance counting (63) implemented in BEAST v 1.8.4. Site-wise mean amino
acid diversity was calculated using the Python script shown in SI Appendix,
Supplementary Method.
Model Construction. Structural models of N-linked glycan presentation on
LASV GPC were created using the trimeric crystal structure [PDB ID code 5VK2
(10)], complex-, hybrid-, and high mannose-typeN-linked glycans (PDB ID codes
4BYH, 4B7I, and 2WAH, respectively). The most-dominant glycoform presented
at each site, as observed on LASV GPC when produced in MDCK cells, was
modeled onto the N-linked carbohydrate attachment sites in Coot (64).
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